AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)

CAPS Rating: 2 out of 5

Results 1 - 8 of 8

Recs

0
Member Avatar pchop12316 (76.28) Submitted: 12/18/2014 2:20:13 PM : Underperform Start Price: $0.87 AVEO Score: +11.20

right move now

Recs

0
Member Avatar Aurum (51.74) Submitted: 7/29/2014 12:48:52 PM : Outperform Start Price: $1.26 AVEO Score: -42.57

Part of a broader pick of micro cap biotechs with encouraging preliminary clinical trial data and significant upside.

Recs

0
Member Avatar TerryHoodSr (62.30) Submitted: 6/16/2014 10:42:24 AM : Outperform Start Price: $1.28 AVEO Score: -45.42

AVEO $1.7/share in cash

Recs

0
Member Avatar rossodell3 (< 20) Submitted: 4/16/2014 7:29:44 AM : Outperform Start Price: $1.35 AVEO Score: -53.77

I was on an Aveo trial drug and it did it's job quite well I tried the other drugs and switched and now cancer free. I checked back with some that i got to know and they lost their battle so i thank with alittle time and with out other drug company intferance Aveo will grow in the next year Good Luck in the fight with this terrible diesase

Recs

0
Member Avatar NoblyNaive (80.65) Submitted: 5/1/2013 2:37:31 PM : Outperform Start Price: $5.49 AVEO Score: -116.14

Short term play, based on chart action and news that this company is not dead yet: Near 52-week (or is it longer?) low, after approx 33% drop basd on bad news. The plan: Expect lots of price chop, so wait until the volatility takes it high and get out before news on tests breaks next month.

Recs

0
Member Avatar efarev (99.15) Submitted: 4/25/2011 12:39:57 AM : Outperform Start Price: $13.50 AVEO Score: -151.92

AVEO's tivozanib works by inhibiting all three VEGF receptors (it is a pan-VEGF inhibitor). Genentech/Roche's Avastin is another drug that hits VEGF and it is one of the top selling Biologics on the market. Eventually it sounds like AVEO has plans to take on Avastin as a safer alternative, but that is probably a ways down the road. In the nearer term, the TIVO-1 PIII trial for Renal Cell Carcinoma (RCC) is going head to head against sorafenib (Nexavar®) with results expected in mid-2011.

PII tivozanib data released by AVEO look good and Astellas liked the data enough to sign a nice partnership deal. The only thing that worries me a bit is that all the clinical sites for the PII trial were in Russia and India only. For me though, the bottom line with AVEO is the science is compelling and if AVEO succeeds with TIVO-1 it could have a blockbuster on its hands...I like the risk reward.

Recs

0
Member Avatar EclecticRecluse (80.31) Submitted: 2/22/2011 12:58:10 PM : Underperform Start Price: $13.89 AVEO Score: +151.10

Poor Forward Earnings Estimate

Recs

0
Member Avatar 1963spencer (40.94) Submitted: 10/20/2010 11:02:11 AM : Outperform Start Price: $15.24 AVEO Score: -170.72

I have RCC. Stinks but I am all for any biotech company that takes the time to perhaps find a cure. Phase 3 trials are looking good. So yea they are going to get any financing needed. Look forward to mid 2011!

Results 1 - 8 of 8

Featured Broker Partners


Advertisement